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ABSTRACT 
Background and Aims: In April 2015, the UK government enacted a temporary class drug 
order (TCDO) on ethylphenidate in response to reported harms associated with its use, in 
particular an outbreak of infections among people who inject drugs (PWID) in Lothian, 
Scotland. This study assesses the effect that the TCDO had on reducing the most common 
infections identified during the outbreak; Streptococcus pyogenes (S. pyogenes) and 
Staphylococcus aureus (S. aureus).  
Methods: The outbreak was split into a pre-intervention period (35 weeks) and a post-
intervention period (26 weeks) based around the date of the TCDO. Segmented negative 
binomial regression models were used to compare trends in weekly counts of infections 
between the pre and post intervention periods.  
Results: There were 251 S. pyogenes and/or S. aureus infections recorded among 211 
PWID between February 2014 to December 2015 — 171 infections in the pre intervention 
period and 51 in the post-intervention period. Significant trend changes in weekly S. 
pyogenes and/or S. aureus infections following the TCDO were found (RR 0.88, 95% CI 
0.82–0.94). PWID who self-reported using novel psychoactive substances (NPS) were at 
higher risk of acquiring these infections (RR 1.81, 95% CI 1.12–2.93), particularly when 
comparing the risk of infection with NPS use for a specific strain, S. pyogenes emm76.0, 
against the risk of infection with NPS use for S. pyogenes (emm types other than emm76.0) 
(RR 3.49, 95% CI 1.32–9.21).   
Conclusions: The ethylphenidate temporary class drug order was effective in reducing 
infections among people who inject drugs during an outbreak situation in Lothian, 
Scotland. Legislative interventions aimed at decreasing accessibility and availability of 
particular substances can play an important role in the public health response to disease 
outbreaks linked to use of NPS. 
 
Abstract word count: 285  
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INTRODUCTION 
The rapid rise in availability and diversity of Novel Psychoactive Substances (NPS) in 
recent years poses particular challenges for public health and policymakers. By 2014, the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) were reportedly 
monitoring over 450 different NPS, including 101 new substances reported for the first 
time that year [1].  
Historically, administration of NPS has been mainly via non-injecting routes [2], however 
evidence in recent years indicates a culture of NPS use among people who inject drugs 
(PWID) in addition to, or as a substitute for, traditional psychoactive substances such as 
heroin [1,3]. It has also been suggested that some NPS users have switched from snorting 
to injecting synthetic cathinones (e.g. mephedrone) [2].  
NPS use by PWID is associated with high frequencies of injecting events and equipment 
sharing [2], and related morbidity and mortality [1,4,5]. Notably, increased frequency of 
injecting is associated with skin and soft tissue infections (SSTIs) at injecting sites [6]. A 
number of 'outbreaks' of NPS-related harm have occurred amongst PWID in recent years. 
In Dublin (Ireland), an outbreak of recent HIV infection among PWID was associated with a 
synthetic cathinone ('Snowblow'), with daily injectors being at highest risk [7]. Increases in 
HIV incidence among PWID in Hungary and Romania have also recently been reported, 
again related to emergence of NPS that require frequent injection [8,9].  
In 2014, an outbreak of severe SSTIs, bacteraemias and infective endocarditis among PWID 
was identified in the Lothian region of Scotland. Specifically, the outbreak was identified 
following a rapid rise in individuals presenting with Streptococcus pyogenes (S. pyogenes) 
infections and Staphylococcus aureus (S. aureus) bacteraemia and soft tissue infections [10]. 
The former involved a number of presentations with the same strain (emm76.0). Enhanced 
surveillance of those affected at the onset of the outbreak identified those involved as 
mainly former heroin injectors and linked most cases to injection of an NPS known locally 
as 'Blue' or 'Burst'. Further investigation revealed Blue/Burst to contain ethylphenidate; a 
stimulant NPS which shares chemical similarities to methylphenidate. Ethylphenidate use 
has been associated with intensive short 'rushes' and frequent injecting episodes [11].  
A key response by governments to the rise in NPS use and related harms has been the use 
of legislation, principally aimed at prohibiting availability and use of particular substances, 
and reducing associated harms. In the UK, temporary class drug orders (TCDOs) have been 
used to re-classify the legal status of a number of NPS including methoxetamine (February 
2013) and benzofuran analogues (June 2013). In response to harms related to 
ethylphenidate use in the UK, in particular the Lothian outbreak, the UK Government 
enacted a TCDO against it and other derivatives of methylphenidate in April 2015. The 
TCDO made it illegal to sell or supply substances containing ethylphenidate from 10 April 
2015 onwards. We aimed to determine whether the TCDO had contributed to a reduction 
in infections among PWID in Lothian. Another goal was to determine whether the TCDO 
had reduced the incidence of infections among NPS users identified within the outbreak. 
Specifically the aims were to: 
• Evaluate the impact of the ethylphenidate TCDO on reducing the most common 
infections (S. pyogenes and/or S. aureus infections) among PWID or those with a 
connection to PWID during the Lothian outbreak in 2014/2015. 
• Identify if there is an association between NPS-injecting and a specific subtype of 
causative bacteria. In particular, if there is a link between S. pyogenes emm76.0 




The Lothian health board region serves a population of around 800,000 people and 
incorporates Edinburgh, the capital city of Scotland (estimated population: 500,000). There 
are an estimated 10,000 problem drug users in Lothian [12] and over 3,000 PWID [13]. 
Data 
Enhanced surveillance initiated during outbreak investigation involved microbiology 
laboratories in Lothian (Edinburgh Royal Infirmary and St John's hospital, Livingston) 
notifying all cases of S. pyogenes and/or S. aureus positive isolates that had a connection to 
PWID to the Health Protection Team in Lothian. All hospital and primary care microbiology 
samples from NHS Lothian are processed in these two laboratories. Data was collected 
consistently from both sites throughout the study period, ensuring that ascertainment of 
NPS associated infection across the whole of Lothian was as complete and comprehensive 
as possible. Hospital records for each case were reviewed to gather information on gender, 
age group, self-reported drug use, sample date and subtype of infection. For individuals 
whose samples cultured one or both of those organisms, the date of their first isolate 
within 2014/2015 was used in this analysis as representing the date of initial infection.  
Analysis was performed on instances of different S. pyogenes and S. aureus infections. S. 
pyogenes infections were categorised as 'emm76.0' and 'other emm type' depending on 
which emm type of S. pyogenes was identified or if the emm type was not known due to 
there being no S. pyogenes isolate available for emm typing. If a PWID sample cultured both 
S. pyogenes and S. aureus on the same date, then this was counted as a single coinfection. 
However if a PWID sample cultured S. pyogenes and S. aureus on different dates, these were 
counted as two separate infections. Furthermore, one PWID cultured different emm types 




We wished to identify if the ethylphenidate TCDO was effective in reducing the incidence of 
infection due to specific bacteria (particularly S. pyogenes emm76.0 which through 
snapshot surveillance and emm typing for two weeks during the outbreak of all S. pyogenes 
isolates from all patients in Lothian, appeared to be only circulating in the PWID 
community or close contacts of PWIDs) or if it was only more generally effective in 
reducing the most common infections under consideration regardless of the causative 
bacteria. Therefore, the causative bacteria were grouped in the following ways: 
1. S. pyogenes (all emm types) and/or S. aureus (n = 251) 
2. S. pyogenes (emm76.0, n = 68) (emm types other than emm76.0, n = 40) 
3. S. aureus (excluding coinfection with S. pyogenes) (n = 143) 




A number of key dates were considered for analysis, particularly for defining the time 
periods before and after intervention. 
• 04 April 2014 (Week 14 2014): First S. pyogenes emm76.0 isolate identified 
(retrospectively) in Lothian (from PWID). 
• 29 September 2014 (Week 40 2014): Awareness of a cluster of PWIDs with S. pyogenes 
infections presenting to Edinburgh Royal Infirmary for surgical intervention and 
notification of the cluster to Public Health. 
• 10 April 2015 (Week 15 2015): Introduction of UK-wide ethylphenidate TCDO. 
• 22 October 2015 (Week 43 2015): Forfeiture Order under the General Product Safety 
Regulations 2005 granted. Edinburgh's head shops (shops selling drug-related 
paraphernalia) [14] and other retailers ceased trading NPS of all types from October 
2015. 
Note that week numbers refer to the ISO-week standard created by the Internal 
Organisation for Standardisation (ISO). This is a leap week calendar system where years 
have 52 or 53 weeks and are numbered in a standardised fashion. Specifically, week 1 is 




Segmented negative binomial regression on weekly counts of infections was used to 
evaluate the impact of the TCDO. Segmented regression is a robust modelling method for 
analysing interrupted time series (ITS) data [15] and allows the data to be modelled by two 
time periods — a pre-intervention period and a post-intervention period. Note that the 
negative binomial model was favoured over a Poisson model as the data was 
overdispersed. Serial dependence in weekly infections was assessed by analysing the 
partial autocorrelation function (PACF) of the regression model residuals. In models where 
significant autocorrelation was identified, this was accounted for by using a GLARMA 
(generalised linear autoregressive moving average) model [16,17]. Model fits using 
different types of regression model were assessed using AIC (Table S1).  
Although the TCDO came into effect on week 15 2015, a time delay was included to make 
the post-intervention period start in week 17. This delay is required as we assumed that 
individuals could have been sourcing NPS up until the TCDO but may not have consumed 
their drugs immediately, and therefore could have presented with infection later. Hence, 
any potential reduction in cases due to the TCDO would not be observed until after a delay. 
We decided that the post-intervention period could not run past the date of the forfeiture 
order because in following period, it is difficult to attribute impacts exclusively to the 
TCDO.  
The start of the pre-intervention period (week 34 2014) was chosen based on when PWID 
were presenting with infections almost every week. This period lasted until the end of 
week 16 2015 (19 April); 35 weeks in total. The post-intervention period started on week 
17 2015 (20 April) and up to the end of the week closest to the forfeiture order (week, 42 
2015; 18 October); 26 weeks in total.  
Separate models were used for different groups of causative bacteria (S. pyogenes and/or S. 
aureus, S. pyogenes and S. aureus). All models had four explanatory variables in common — 
number of weeks since the start of the pre-intervention period, a variable indicating pre 
and post-intervention weeks, number of weeks since the start of the post-intervention 
period and a variable to identify individuals who reported NPS use. The S. pyogenes model 
also included a variable to discern S. pyogenes emm76.0 infections and an interaction 
between NPS use and S. pyogenes emm76.0 infections. These models enable the change in 
level and trend pre and post intervention to be investigated and also allows NPS use to be 
considered. The interaction term allows the risk of infection for NPS users to be compared 
between S. pyogenes emm76.0 infections and S. pyogenes (emm types other than emm76.0). 
A 5% value was used to test for statistical significance. 
 
RESULTS 
There were 211 individuals who had a total of 251 S. pyogenes and/or S. aureus infections 
between February 2014 and the end of 2015. Most of these occurred between, and 
including, week 34 2014 and week 20 2015 (a few weeks after the TCDO — Figure 1). 
Cases were predominantly male and aged between 26–50; almost two-thirds of cases 
identified themselves as NPS users (Table 1). The 'NPS user' group comprised those who 
self-reported to be NPS users without current heroin use (n = 27) and those who reported 
that they were currently using both NPS and heroin (n = 106) (data not shown).  
[Insert Table 1 about here]  
There were no significant differences by age and gender between individuals with S. 
pyogenes infections compared to those with S. aureus infections. A higher proportion of 
cases infected with S. aureus reported heroin use (25.2%, n = 36/143) compared with cases 
infected with S. pyogenes (15%, n = 16/107), however the difference was not significant (𝜒2 
= 3.3, p = 0.07). Conversely, a larger proportion of PWIDs infected with S. pyogenes 
reported use of NPS (68.2%, n = 73/107) compared to those infected with S. aureus (63.6%, 
n = 91/143) but this difference was not significant (𝜒2 = 0.4, p = 0.535). Of those with S. 
pyogenes infections, 63.6% (n = 68/107) were due to emm76.0. 
 
TCDO Impact 
There were marked reductions in the incidence of weekly infections due to the groups of 
causative bacteria following the TCDO (Table 2). The largest reduction was in S. pyogenes 
emm76.0 infections where the weekly incidence was 4 times larger in the pre-intervention 
period (1.6 infections per week) compared with the post-intervention period (0.4 
infections per week) and which continued to appear only to be affecting the PWID 
population throughout the outbreak. In contrast, the incidence of weekly infections of S. 
pyogenes with emm types other than emm76.0 remained similar before (0.6 infections per 
week) and after the TCDO (0.4 infections per week). Table 2 also shows that only a small 
number of infections in 2014 and 2015 occurred at times outwith the time periods chosen 
for analysis, in particular for S. pyogenes emm76.0 infections. This gives assurance that the 
chosen time periods are appropriate for the research questions under investigation.  
[Insert Table 2 about here]  
The relative risks (RRs) and corresponding 95% confidence intervals (CIs) in Table 3 show 
that the trend in weekly infections was significantly lower following the TCDO for all 
causative bacteria under consideration. These trend changes are illustrated in Figure 1. 
Note that only two models (S. pyogenes and/or S. aureus and S. aureus alone) accounted for 
first-order autocorrelation and the S. pyogenes model did not as no significant 
autocorrelation was detected there. Furthermore, NPS-injecting significantly increased the 
risk of infections due to S. pyogenes (all emm types) and/or S. aureus (RR 1.81, 95% CI 
1.12–2.93) but not due to S. aureus alone (RR 1.58, 95% CI 0.94–2.68). In the S. pyogenes 
model, an interaction term between NPS use and S. pyogenes emm76.0 infections was 
included and this shows that NPS-injecting increased the risk of infection due to S. pyogenes 
emm76.0 much more than for emm types other than emm76.0 (RR 3.49, 95% CI 1.32–9.21).  
[Insert Table 3 about here]  
[Insert Figure 1 about here] 
 
DISCUSSION 
To date, few quantitative studies have attempted to assess the effectiveness of policies that 
legislate against the availability of NPS. This study differs from those that have been 
conducted previously [18–21] as it is the first to examine the impact of a TCDO that was 
enacted in response to a disease outbreak. The ethylphenidate TCDO enacted in April 2015 
was highly effective in reducing incidence of S. pyogenes and S. aureus infections among 
PWID during an outbreak in Lothian, Scotland. Many of these PWID self-reported using NPS 
which was associated with an increased risk of acquiring infection, especially those due to 
S. pyogenes emm76.0. Dramatic reductions in infections due to S. pyogenes and S. aureus 
following the TCDO were observed among individuals that reported NPS use.  
Introducing policies that prohibit the availability and/or use of certain psychoactive 
substances may result in immediate positive public health impacts but also lead to adverse 
and unintended consequences [22,23]. Opponents to the use of legislative prohibition 
measures argue they are overly simplistic and often ineffective, either because prohibition 
will move a particular NPS to the black market or that particular NPS will be replaced by 
new drugs [22,24–26]. To counter these criticisms, it is essential to make assessments of 
how successful these measures have been in achieving intended outcomes.  
The outbreak arose due to the increasing prevalence of injecting ethylphenidate in Lothian 
combined with a change in injecting behaviour associated with injection of this drug. 
Changes included sharing of needles (which occurred as communal injecting in unhygienic 
conditions was not uncommon [11]), use of dirty injecting paraphernalia, injection of non 
sterile drug diluents, preferential injecting into anatomical sites known to harbour bacteria 
associated with causing severe SSTIs, poor personal hygiene and hand hygiene in 
conjunction with multiple necrotic, ulcerating or discharging skin lesions and compulsive, 
repetitive redosing associated with ethylphenidate use [27] (some individuals reported 
injecting up to 30 times daily), with each repeated skin puncture raising the possibility of 
infection [28]. In this predicament where NPS-injecting clearly had high addictive potential 
and was causing serious harm, availability of the implicated NPS (here, ethylphenidate 
based) is an important factor (as evidenced previously by the experiences of NPS users in 
Ireland [29] and Scotland [30]) and the urgency at which a TCDO could be executed was 
crucial in preventing individuals from easily obtaining ethylphenidate. As a consequence of 
reduced availability, risky NPS associated injecting behaviours and consequently infective 
complications of injecting NPS were positively influenced.  
Enhanced surveillance facilitated the collection of richer data including information on 
individual drug use and laboratory testing. The initial dominance of S. pyogenes emm76.0 
was striking as prior to the outbreak it was an uncommon emm type in the United Kingdom 
and even rarer in Scotland [31,32]. The discovery early in the outbreak that emm76.0 S. 
pyogenes was being transmitted solely within the PWID community (or their immediate 
contacts) allowed investigators to more easily identify links between cases and that the 
common factor between many of the cases was likely to be NPS-injecting.  
One of the strengths of this study is that it measured the impact of the TCDO against a 
defined and patient-centred clinical outcome (infective complications of injecting). This is 
in a similar vein to the study by Wood et al. [21] which measured impact against numbers 
of emergency department visits for acute toxicity from patients with self-reported 
mephedrone use. In contrast, previous studies have assessed effectiveness of legislative 
prohibition using measures with perhaps, greater degrees of uncertainty with respect to 
their ability to measure public health impacts. For instance, Hill et al. [18] and Loeffler et al. 
[33] measured the impact of the temporary bans by examining numbers of calls to 
information services for substance toxicity. Here, the uncertainty comes from some 
enquiries being for information only rather than being related to actual cases and also 
fluctuating levels of knowledge regarding NPS by members of the public and health 
professionals over time.  
Another strength of this study is the decision to use segmented regression in a GLARMA 
model [16,17] to analyse the data split into pre and post-intervention time periods. In the 
absence of randomisation or clinical trial data, segmented regression has been suggested 
by Kontopantelis et al. [34] as the 'next best' approach for analysing the effect of 
interventions. Furthermore, the method has been suggested to be powerful, robust and 
allows substantial flexibility in controlling how the intervention effect is modelled and 
interpreted [15,35,36]. In this analysis, the flexibility of the approach allowed for trends in 
numbers of infections pre and post-intervention to be modelled while accounting for self-
reported NPS use and serial dependence in the time series data.  
The time-series analysis undertaken in this study is confined to a local area (Lothian), 
therefore the application of the findings to other territories, particularly those at a national 
population level, should be done with caution. Further, we were unable to determine 
whether the results were confounded by the rate of drug use or drug injecting over time 
due to an absence of relevant data. The most recent prevalence estimates available for 
Lothian date back to 2012/13 (problem drug use) [12] and 2006 (PWID) [13].  
Despite a programme of enhanced surveillance undertaken during the outbreak, it is 
possible that eligible cases were not identified and therefore not included within our 
analysis. However, extensive efforts were made to coordinate data collection between 
secondary care, laboratories and public health during the outbreak meaning that the extent 
of missing data is likely to be minimal. A further potential limitation in our methodology is 
the use of self-reported data on drug use and the potential for social desirability bias in 
responses. Prior research has concluded that drug user self-reports offer a "sufficiently 
reliable and valid" method for describing drug use [37] and related harms and we thus 
assume similar levels of validity and reliability in this study.  
Another possible confounder was the discovery latterly during the outbreak that some 
heroin being injected by the PWID community was adulterated with ethylphenidate-based 
NPS resulting in heroin injectors manifesting the infections due to causative bacteria 
associated with NPS-injecting. This point may help to explain one of our findings. Although 
S. pyogenes emm76.0 infections were strongly linked to NPS-injecting, we did not find a 
significant difference in the change in mean level of S. pyogenes emm76.0 infections 
following the TCDO between those with and without self-reported NPS use. This may have 
been because the individuals who acquired S. pyogenes emm76.0 infections but did not 
report NPS use may have in fact been NPS users unknowingly or direct contacts of those 
PWIDs with S. pyogenes skin infections. This could be explained if the emm76.0 S. pyogenes 
was transmitted between individuals by a mechanism other than through injecting NPS 
such as close contact in unhygienic conditions.  
The study was not able to evaluate the impact of the TCDO on all infections associated with 
the outbreak. For example, incidence of S. aureus endocarditis, an infection which had one 
of the largest impacts on the health service during the outbreak and was characterised by 
severe morbidity and, in some cases, mortality, reduced dramatically post TCDO. However, 
the relatively small numbers of these infections in the pre-intervention period precluded 
evaluation using a modelling approach.  
It is challenging to isolate the effect of the TCDO from the impact of other ongoing public 
health responses to the outbreak that were happening simultaneously. For instance, prior 
to the introduction of the TCDO in April 2015, several head shops across Lothian were 
identified as trading ethylphenidate. A letter from the Director of Public Health (DPH) was 
sent to 24 head shops on 19 March 2015 requesting that they cease selling these 
substances, highlighting the significant health impact of their use at both an individual and 
population level. In addition, proactive communication raising awareness of this outbreak 
was targeted to the 'at risk' population and those services/agencies in contact with the at 
risk population. It is possible that these communications contributed to a reduction in 
ethylphenidate use and associated infections in Lothian. However, the timing of the abrupt 
drop in incidence of infective complications of injecting and significant change in trend 
following the TCDO point to the TCDO being the crucial intervention above all others in 
impacting availability, use and related infection(s).  
In this study, the TCDO was enacted on 10 April 2015 but a decision was made to start the 
post-intervention period on 20 April 2015 (week 17). This is because we hypothesised that 
individuals could source ethylphenidate up to April 10 but purchased drugs would not all 
be consumed immediately. Here, the choice of how much lag-time to include is subjective. 
For this reason, the sensitivity of results to the chosen start date for the post-intervention 
period was tested by also starting the period on 13th and 27th April (weeks 16 and 18). 
Under all alternative scenarios, the results were similar (Tables S2–S3) and conclusions 
drawn were largely consistent with our original choice of 20th April. Only one notable 
difference was found, which occurred when using 27th April — the trend change in the S. 
pyogenes model was no longer significant. The is understandable as the results from that 
model are more sensitive to changes due to there being less infections (compared with the 




NPS use and its related harm continue to pose risks for public health internationally, 
including in the UK [38]. Before legislation can be enacted to prohibit NPS, sufficient 
evidence must be accumulated. In the situation where these NPS are causing severe harm 
to individuals, urgent action is needed and the strict requirements for implementing 
legislation may need to be circumvented; this is the where TCDOs offer most value. This 
study demonstrates that the TCDO for ethylphenidate was effective in disrupting the 
transmission of infection among PWID in Lothian, Scotland. 
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 Figure 1 Observed and predicted weekly infections for groups of causative bacteria split by 
PWID with/without NPS use (those without are 'Other'). Predictions were made using 
segmented negative binomial regression. The S. pyogenes and/or S. aureus model and 
S.aureus alone model accounted for first-order autocorrelation. The green dashed lines 
show the start of the pre-intervention period and the end of the post-intervention period. 
The red dashed line shows the changeover date (20 April 2015) from pre to post-
intervention which occurs later than the date the TCDO was enacted (10 April 2015) due to 
the inclusion of a delay. 
Table 1 Characteristics of cases of infection split into S. pyogenes (all emm types) and/or S. 
aureus, S. pyogenes (all emm types), and S. aureus (excluding coinfection with S. pyogenes). 
  
S. pyogenes and/or 
S. aureus  
S. 
pyogenes  S. aureus 
  n %  n %  n % 
Gender Female 58 27.5  31 29.0  41 28.7 
 Male 153 72.5  76 71.0  102 71.3 
Age 20 and under 1 0.5  0 0.0  1 0.7 
 21–25 9 4.3  4 3.7  6 4.2 
 26–30 29 13.7  14 13.1  22 15.4 
 31–35 59 28.0  35 32.7  37 25.9 
 36–40 49 23.2  20 18.7  33 23.1 
 41–45 36 17.1  21 19.6  27 18.9 
 46–50 23 10.9  9 8.4  16 11.2 
 51+ 5 2.4  4 3.7  1 0.7 
Drug Use (Self-
Reported) 
NPS User 133 63.0  73 68.2  91 63.6 
Heroin User 48 22.7  16 15.0  36 25.2 
 ex-PWID 18 8.5  9 8.4  12 8.4 
 Other 9 4.3  7 6.5  3 2.1 
 PWID (unknown 
type) 
2 0.9  2 1.9  0 0.0 
 No recent 
information 
1 0.5  0 0.0  1 0.7 
S. pyogenes emm 
Type 
emm76.0    68 63.6    
  
Table 2 Numbers and weekly rate of infections within the pre and post-intervention 
periods by infection group. Rates were estimated using a pre-intervention period of 35 













S. pyogenes (all emm types) and/or 
S. aureus 
171 4.9  51 2.0 29 
S. pyogenes (emm76.0) 56 1.6  10 0.4 2 
S. pyogenes (emm types other than 
emm76.0) 
21 0.6  11 0.4 8 
S. aureus (excluding coinfection 
with S. pyogenes) 
94 2.7  30 1.2 19 
  
Table 3 Relative risks and 95% confidence intervals estimated from segmented negative 
binomial regression models for three groups of infections. The S. pyogenes and/or S. aureus 
model and S.aureus alone model accounted for first-order autocorrelation. 
 RR 95% CI p 
S. pyogenes (all emm types) and/or S.aureus    
    Intercept 1.12 0.59 – 2.11 0.728 
    Trend: Pre-TCDO 1.02 0.99 – 1.05 0.229 
    Level change following TCDO 1.11 0.46 – 2.70 0.820 
    Trend change following TCDO 0.88 0.82 – 0.94 <0.001 
    NPS User 1.81 1.12 – 2.93 0.016 
S. pyogenes    
    Intercept 0.36 0.18 – 0.72 0.004 
    Trend: Pre-TCDO 1.00 0.97 – 1.02 0.762 
    Level change following TCDO 0.97 0.39 – 2.45 0.956 
    Trend change following TCDO 0.93 0.87 – 1.00 0.037 
    NPS User 1.14 0.55 – 2.35 0.726 
    S. pyogenes emm76.0 0.86 0.40 – 1.87 0.708 
    Interaction: NPS User with emm76.0 3.49 1.32 – 9.21 0.012 
S. aureus    
    Intercept 0.41 0.19 – 0.88 0.022 
    Trend: Pre-TCDO 1.05 1.01 – 1.08 0.004 
    Level change following TCDO 0.87 0.40 – 1.91 0.736 
    Trend change following TCDO 0.83 0.77 – 0.90 <0.001 
    NPS User 1.58 0.94 – 2.68 0.087 
  
